Kura Oncology, Inc. (KURA) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Kura Oncology, Inc.
Address
12730 High Bluff Drive
San Diego, CA 92130
United States of America (the)
Phone
858 500 8800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
192
First IPO Date
September 16, 2015
Key Executives
| Name | Title | Pay | Year Born |
| Troy Edward Wilson | Chairman, Chief Executive Officer & President | 1.44M | 1969 |
| Teresa Brophy Bair | Chief Legal Officer & Corporate Secretary | 745,021 | 1971 |
| Brian T. Powl | Chief Commercial Officer | 814,998 | 1974 |
| Mollie Leoni | Chief Medical Officer | 855,297 | 1978 |
| Kathleen Ford | Chief Operating Officer | 926,501 | 1947 |
| Roger Bakale | Senior Vice President of Manufacturing & Supply Chain | 0 | N/A |
| Francis J. Burrows | Chief Scientific Officer | 0 | 1962 |
| Thomas Doyle | Senior Vice President of Finance & Accounting | 0 | 1971 |
| Greg Mann | Senior Vice President of Investor Relations & Corporate Affairs | 0 | N/A |
| Samir Vattompadam | Senior Vice President of Global Program Leadership | 0 | N/A |
Description
Kura Oncology, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to discovering and advancing cancer treatments within the United States. Its therapeutic portfolio primarily features small-molecule compounds engineered to combat various cancers. Among its leading drug candidates is ziftomenib, a small-molecule agent designed to disrupt the interaction of menin-Lysine K-specific Methyltransferase 2A proteins. This inhibitor is being developed for specific genetic forms of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Another prominent candidate is tipifarnib, an orally administered farnesyl transferase inhibitor currently undergoing Phase II clinical assessment for both solid tumors and blood-related conditions. The company has also established a clinical collaboration with Novartis to evaluate the combined therapeutic potential of tipifarnib and alpelisib. This joint effort targets patients with head and neck squamous cell carcinoma whose tumors exhibit HRAS overexpression or specific PIK3CA mutations or amplifications. Founded in 2014, Kura Oncology, Inc. operates from its headquarters in San Diego, California.
